EBF
EBF
EBF
European
Bioanalysis
Forum


EBF vzw is the registered non-profit organisation of the European Bioanalysis Forum

 

Reconnecting after Quarantine

10-11 June 2021

YSS Slides 2021

PDF renditions of the PowerPoint presentations can be viewed and downloaded from this page by clicking the specific point on the program. The program itself can be viewed and downloaded by clicking here.

Program details of the EBF 7th YSS

10 June 2021
11:30 13:00 Welcome at local sites – local site program as appropriate
13:00 13:10 Welcome
Philip Timmerman
13:10 14:30 Session 1: Achieving better sensitivity and selectivity
Chair/Moderator/Questions: Connor/Mathias/Salvatore
13:10 13:30 Steven Schoemaker – PRA-HS
Chiral derivatization for enhancing sensitivity and speed of the LC-MS/MS determination of the enantiomers of ibuprofen.
13:30 13:50 Claire Szuster – LGC
The diasteromer double-peak dilemma
13:50 14:10 Marco Cirrincione – University of Bologna
Enantiomeric separation of chiral synthetic opioids and metabolites in DBS by UHPLC-HRMS
14:10 14:30 Rosie Penford – GlaxoSmithKline
The identification and development of a fit for purpose biomarker assay using the MSD platform
14:45 15:15 Parallel Session 2
Training Course: the basics of ADA in 30 minutes
presenter: Salvatore Calogero, on behalf of the EBF
14:45 15:15 Parallel Session 3
Training Course: the basics of LC-MS in 30 minutes
presenter: Terrence Hetzel/Connor Walker, on behalf of the EBF
15:30 18:00 Session 4: Miniaturisation and automation
Chair/Moderator/Questions: Michele/Ian/Muriel
15:30 15:50 Liesl Heughebaert – University of Ghent
Near-infrared-based hematocrit prediction of dried blood spots: an in-depth evaluation
15:50 16:10 Camilla Marasca – University of Bologna
Haematic volumetric microsampling for TDM of patients under treatment with lurasidone
16:10 16:30 Bryan van den Broek – Sanquin
Measuring antibodies in capillary blood: improvements by moving from dried blood spot to haematocrit independent micro-sampling
16:30 16:40 short break
16:40 17:00 George Walters – LGC
Automation vs Analyst: The Future of Bioanalysis
17:00 17:20 Sigrid Deprez – University of Ghent
Fully Automated Dried Blood Spot-Based Therapeutic Drug Monitoring of Immunosuppressants
17:20 17:40 John Smeraglia – UCB Pharma
Role of automation in maximizing portfolio value –  the future is now
17:40 18:00 Scott Summerfield – GlaxoSmithKline
Transitioning to an ‘automation-first’ culture in Bioanalysis – our learnings from the last 3 year
18:00 End of Day 1 Q&A
11 June 2021
09:45 Coming online
10:00 11:20 Science Café: “How has Covid-19 changed our future? “
This year, the YSS-OC wants to engage you how Covid-19 impacted our (professional) careers, i.e. things we lost, for good or for bad – things we gained, wanted or unwanted, things we learned about ourselves and our industry. The YSS has prepares a  panel discussion for all of you to contribute
11:30 12:10 Interactive poster viewing session (5-min poster pitch – posters 1 to 7)
Chair/Moderator/Questions: Mathias/Robin
12:10 12:40 Lunch break
12:50 13:30 Interactive poster viewing session (5-min poster pitch – posters 8 to 14)
Chair/Moderator/Questions: Mathias/Robin
13:30 14:10 Was the 6th YSS’ sustainability theme “sustainable”?
13:30 13:50 Katja Zeiser – Nuvisan
Re-Validation concept for an optimized use of resources – what have we achieved?
13:50 14:10 5-min pitches of “what are WE doing on sustainability?”
Connor Walker (Arcinova – A Quotient Sciences Business), Adam Williams (AstraZeneca),  Salvatore Calogero (F. Hoffmann – La Roche) and Ian Dawson (Covance)
14:10 14:40 Plenary Feedback from (local or e-) Science Café round tables
15:00 16:20 Session 5: Novel approaches to ADA/complex assays – how did you overcome them?
Chair/Moderator/Questions: Salvatore/Laura/Tessa
15:00 15:20 Hanna Leins – Nuvisan
One for all – development of a generic ADA assay on the Gyrolab Platform
15:20 15:40 Christina Aniol-Nielsen – NovoNordisk
Calibration-Free Concentration Analysis for Quantification of Anti-Drug Specific Antibodies in Positive Control Antibodies and in Clinical Samples
15:40 16:00 Eugenia Opolka-Hoffmann – F. Hoffmann La Roche (not released for publication) (not released for publication)
The impact of drug/ADA immune complex properties on drug clearance: an in vivo study and the underlying bioanalytical method
16:00 16:20 Jayshree Maher – LGC
AlphaLISA – An alternative plaform for immunogencitiy assays?
16:40 18:20 Session 6: Biomarkers and CoU: an uphill journey for young scientists?
Chair/Moderator/Questions: Tessa/Adam/Terence
16:40 16:50 Philip Timmerman – EBF
Introduction to the session & Background of EBF in relation to Biomarker assay validation
16:50 17:10 Kyra Cowan – on behalf of the EBF
Context of Use versus the BMV – why the discussion?
17:10 17:30 Léa Costes – Sanquin (not released for publication)
Biomarker assays and context of use: two stories, one success
17:30 17:50 Michele Protti – University of Bologna
Pathology biomarkers in animal models of amyotrophic lateral sclerosis: microsampling-based analytical investigation
17:50 18:20 Panel discussion: CoU – an uphill journey for young scientists?
18:20 Closing Remarks and Adjourn